Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 11;75(2):253–265. doi: 10.1002/art.42392

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Patients included in the TULIP‐1 or TULIP‐2 trials and LTE study: treatment randomization and treatment group definitions. ^aThere was an 8‐week safety follow‐up period. ^bPatients randomized to receive anifrolumab 150 mg were all in TULIP‐1. ^cPatients were re‐randomized to receive anifrolumab 300 mg or placebo for the LTE study. TULIP‐1 = Treatment of Uncontrolled Lupus via the Interferon Pathway 1; IP = investigational product; LTE = long‐term extension.